NCT02490865View on ClinicalTrials.gov

Systemic Bioactivity of Inhaled Nebulized RNS60

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Systemic Bioactivity of Nebulized RNS60
Interventions
DRUG

RNS60

RNS60, 4 ml dose nebulized twice daily

DRUG

Normal saline

Normal Saline, 4 ml dose nebulized twice daily

Trial Locations (1)

GU2 7XP

Surrey Clinical Research Centre, Guildford

All Listed Sponsors
lead

Revalesio Corporation

INDUSTRY

NCT02490865 - Systemic Bioactivity of Inhaled Nebulized RNS60 | Biotech Hunter | Biotech Hunter